A drug for acute NAION is currently in phase III clinical trials After glaucoma, the second-most common source of optic nerve damage is Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). We usually describe this to a patient as a “stroke in the eye,” where...
